1 terminated, 1 unknown. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Terminated 1, Unknown 1 |
| Phase 1 | 1 | Unknown 1 |
Follow Angioblast Systems: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of Intramyocardial Injection of Mesenchymal Precursor Cells on Heart Function in People Receiving an LVAD Mesenchymal Precursor cells (RevascorTM), Cryoprotective media alone - Heart Failure | Phase 2 | Terminated | Icahn School of Medicine at Mount Sinai | 10 | 2009-08-01 | 2019-03-05 |
| Safety Study of Allogeneic Mesenchymal Precursor Cells (MPCs) in Subjects With Recent Acute Myocardial Infarction Allogeneic Mesenchymal Precursor Cells (MPCs), Standard-of-care treatment with NOGA® mapping and staged injections. - Myocardial Infarction | Phase 1 / Phase 2 | Unknown | Angioblast Systems | 25 | 2008-03-01 | 2010-02-17 |
Heart Failure (1) · Infarction (1) · Myocardial Infarction (1)
United States (2)
Deborah Ascheim, MD (1) · Emerson C. Perin, MD, PhD (1) · Yoshifumi Naka, MD (1)
P50HL077096 (1)